Under the agreement, Hengrui Pharma has granted Merck exclusive rights to develop, manufacture, and commercialize HRS-5346 worldwide, excluding the Greater China region. Hengrui Pharma will ...

CHICAGO (Reuters) - The highest dose of an experimental drug developed by Eli Lilly significantly reduced levels of a ...

Eli Lilly’s experimental drug, lepodisiran, reduces lipoprotein(a) (Lp[a]) levels by an average of 93.9 per cent in a ...

The deal gives MSD exclusive rights to the HRS-5346 candidate outside the Greater China region and also includes milestone payments tied to development, regulatory, and commercial targets that ...

Furthermore, Merck has entered an exclusive licensing agreement with Jiangsu Hengrui Pharmaceuticals to develop and commercialize HRS-5346, a cardiovascular drug candidate targeting elevated ...

Merck last week signed a licensing agreement with Jiangsu Hengrui Pharmaceuticals to test its experimental Lp(a) pill called HRS-5346. (This story has been corrected to reflect a total of 141 ...

Moreover, Merck has entered into a new licensing agreement with Jiangsu Hengrui Pharmaceuticals, granting it exclusive rights to develop and commercialize HRS-5346, an oral small molecule Lp(a ...

Merck last week signed a licensing agreement with Jiangsu Hengrui Pharmaceuticals to test its experimental Lp(a) pill called HRS-5346.

Another week of escalating tariff talks led to a slump across major U.S. stock market indices for the five-day trading period. The S&P 500 dropped nearly 3% for the week, with losses in three of the ...